Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer

Table 1 Clinical characteristics of patients with borderline resectable pancreatic cancer

Preoperative variables	N = 29
Age, years	66 [50–78]
Sex (male)	19 (66%)
ECOG-PS (0/1)	27 (93%)/2 (7%)
Tumor location (Ph/Pb)	24 (83%)/5 (17%)
UICC 7th, Stage (I/II/III)	0/9 (31%)/20 (69%)
Type of tumor-vessel contact
BR-PV	9 (31%)
BR-SMA	19 (66%)
BR-CHA	3 (10%)
BR-CeA	1 (3%)
Tumor size, mm
Before NACRT	29 [17–40]
After NACRT	26 [11–38]
CEA, ng/mL
Before NACRT	3.5 [1.1–28.4]
After NACRT	3.3 [1.5–18.0]
CA 19–9, U/mL
Before NACRT	202.2 [1.0–4626.0]
After NACRT	68.7 [0.6–1530.0]
RECIST classification (PR/SD/PD)	3 (10%)/25 (86%)/1 (3%)
Operative variables	N = 29
Surgical procedure
Pancreaticoduodenectomy	24 (83%)
Distal pancreatectomy	5 (17%)
Portal vein resection	16 (55%)
Partial resection of SMA plexus	27 (93%)
Number of retrieved lymph nodes	21 [5–51]
Blood loss, ml	835 [19–2589]

ECOG-PS Eastern Cooperative Oncology Group performance status, Ph Pancreas head, Pb pancreas body, UICC 7th The Union for International Cancer Control (UICC) classification 7th edition, BR Borderline resectable, PV Portal vein, SMA Superior mesenteric artery, CHA Common hepatic artery, CeA Celiac artery, NACRT Neoadjuvant chemoradiotherapy; RECIST, response evaluation criteria in solid tumors; PR, partial response; SD, stable disease, PD Progressive disease, CEA Carcinoembryonic antigen, CA 19–9 Carbohydrate antigen 19–9

ISSN: 1471-2407